JSPR Aug 2024 20.000 call
| Previous close | 5.80 |
| Open | 5.80 |
| Bid | 6.50 |
| Ask | 10.00 |
| Strike | 20.00 |
| Expiry date | 2024-08-16 |
| Day's range | 5.80 - 5.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
GlobeNewswireJasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress pre
- GlobeNewswire
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Jefferies Global Healthcare Conference at 4:00pm EDT on Wednesday, June 5, 2024. A live webcast
- GlobeNewswire
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments. “We have continued to make stron
